Want to see HK:2487 full AI Analyst Report?
2487 Stock Chart & Stats
HK$4.59
-HK$0.09(-1.60%)
At close: 4:00 PM EST
HK$4.59
-HK$0.09(-1.60%)
Day’s Range― - ―
52-Week RangeHK$2.05 - HK$12.00
Previous CloseN/A
Volume1.53M
Average Volume (3M)399.60K
Market Cap
HK$835.21M
Enterprise ValueHK$1.02B
Total Cash (Recent Filing)HK$789.16M
Total Debt (Recent Filing)HK$317.53M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding374,533,900
10 Day Avg. Volume272,590
30 Day Avg. Volume399,603
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.52
Price to Sales (P/S)4.01
P/FCF Ratio-4.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)HK$580.00M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginThe sharp revenue rebound indicates improving commercial traction after near-flat growth in 2024. Maintaining a gross margin near 46% provides a foundation for future operating leverage if the company can scale products and control development costs.
Manageable LeverageModerate leverage and a still-positive equity base provide more financial flexibility than a highly indebted balance sheet. This may help the company fund ongoing development while reducing immediate solvency pressure as it works toward profitability.
Improving Cash BurnAlthough cash generation remains negative, the substantial year-over-year reduction in operating cash burn suggests better cost control or working-capital dynamics. Continued improvement could extend funding runway and reduce future financing dependence.
Bears Say
Deep Operating LossesLosses remain exceptionally large relative to revenue, showing that the business is still far from sustainable operating economics. Persistent investment requirements could delay break-even and make future profitability highly dependent on strong revenue scaling.
Negative Free Cash FlowNegative operating and free cash flow means internal operations do not yet fund the business. Until cash flow turns sustainably positive, the company may rely on external financing, creating dilution or liquidity risks over the medium term.
Declining Equity And Negative ROEShrinking equity alongside deeply negative returns indicates that ongoing losses are eroding the capital base. If this trend persists, financial flexibility may weaken and additional funding could become increasingly important to maintain operations.
Cutia Therapeutics News
2487 FAQ
What was Cutia Therapeutics’s price range in the past 12 months?
Cutia Therapeutics lowest stock price was HK$2.04 and its highest was HK$12.00 in the past 12 months.
What is Cutia Therapeutics’s market cap?
Cutia Therapeutics’s market cap is HK$835.21M.
When is Cutia Therapeutics’s upcoming earnings report date?
Cutia Therapeutics’s upcoming earnings report date is Aug 27, 2026 which is in 9 days.
How were Cutia Therapeutics’s earnings last quarter?
Cutia Therapeutics released its earnings results on Mar 24, 2026. The company reported -HK$0.304 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.304.
Is Cutia Therapeutics overvalued?
According to Wall Street analysts Cutia Therapeutics’s price is currently Overvalued.
Does Cutia Therapeutics pay dividends?
Cutia Therapeutics does not currently pay dividends.
What is Cutia Therapeutics’s EPS estimate?
Cutia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cutia Therapeutics have?
Cutia Therapeutics has 374,533,900 shares outstanding.
What happened to Cutia Therapeutics’s price movement after its last earnings report?
Cutia Therapeutics reported an EPS of -HK$0.304 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.951%.
Which hedge fund is a major shareholder of Cutia Therapeutics?
Currently, no hedge funds are holding shares in HK:2487
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cutia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.87%
Trailing 12-Months
Company Description
Cutia Therapeutics
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
Technical Analysis
JW (Cayman) Therapeutics Co. Ltd.
―
Mabpharm Limited
―
Sirnaomics Ltd.
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―